All coverage
Vaccine Makers Are Asked to Expand Safety Studies on Children (Published 2021)
By Sharon LaFraniere, Sheryl Gay Stolberg & Noah Mercer Weiland
Pfizer Revenue Boosted by Covid-19 Drugs
By Felix Richter
Efficacy of Pfizer/BioNTech Covid vaccine slips to 84% after six months, data show
By Matthew Herper & Damian Garde
AstraZeneca Loses Money on Covid-19 Vaccine for Second Straight Quarter
By Cecilia Butini & Jenny Strasburg
Pfizer data suggest third dose of Covid-19 vaccine 'strongly' boosts protection against Delta variant
By Jacqueline Howard
Moderna says it plans to expand Covid vaccine trial for kids 5 to 11, will seek FDA OK as early as year-end
By Berkeley Lovelace & Berkeley Lovelace Jr.
Pfizer now expects COVID vaccine sales to reach $33.5B this year, a whopping $7.5B bump from its estimate 3 months ...
By Kevin Dunleavy
EXCLUSIVE AstraZeneca exploring options for COVID-19 vaccine business - executive
By Pushkala Aripaka & Alistair Smout
Pfizer says 2021 COVID-19 vaccine sales to top $33.5 bln, sees need for boosters
By Michael Erman & Manas Mishra
Pfizer's CEO says Covid vaccine effectiveness drops to 84% after six months
By Kevin Stankiewicz
Pfizer and Moderna Are Expanding Vaccine Studies of Kids 5 to 11
By Sharon LaFraniere, Sheryl Gay Stolberg & Noah Mercer Weiland